Li Zhan, Liu Yingqi, Ding Wei, Liu Yue, Li Wang, Guan Shanshan, Liu Xianjun, Wang Guizhen, Liu Qiong, Jiang Chunwa, Peng Xinli, Li Hao, Li Zhandong, Li Jing
School of Biological and Food Engineering, Jilin Engineering Normal University, Changchun, China.
School of Chemistry and Life Sciences, Changchun University of Technology, Changchun, China.
Front Pharmacol. 2025 Jul 3;16:1588037. doi: 10.3389/fphar.2025.1588037. eCollection 2025.
After recovering from severe acute respiratory syndrome of coronavirus 2 (SARS-CoV-2) acute infection, some patients with corona virus disease 2019 (COVID-19) still are affected by post-acute COVID-19 syndrome (PACS). Traditional Chinese medicine (TCM) has played an important role in the recovery period of COVID-19. As a unique type of Chinese botanical drugs, foods with property of food and medicine homology (FMH) has the dual characteristics of drug and food, which has advantages over usual drugs in safety and daily application. This review analyzed a total of 290 peer-reviewed publications on the progress of dozens of formulas and single botanical drugs, which were systematically collected from the electronic scientific databases, including PubMed, Web of Science, and China National Knowledge Infrastructure (CNKI), as well as other literature sources, such as classic Chinese medicine books. The symptoms of PACS and the advancements in the application of FMH foods in PACS intervention are summarized, and the challenges in the regulatory characteristics and food safety are further discussed. It is expected that the application of FMH foods would bring new opportunity for the treatment and daily intervention of PACS, and this review provides a foundation for the development of PACS intervention foods.
在从新型冠状病毒2(SARS-CoV-2)急性感染引起的严重急性呼吸综合征中康复后,一些2019冠状病毒病(COVID-19)患者仍受到新冠后急性综合征(PACS)的影响。中医在COVID-19的恢复期发挥了重要作用。作为一类独特的中药,具有药食同源特性(FMH)的食物具有药物和食物的双重特性,在安全性和日常应用方面比普通药物具有优势。本综述共分析了290篇同行评议的关于数十种方剂和单一植物药进展的出版物,这些出版物是从电子科学数据库系统收集的,包括PubMed、科学网和中国知网,以及其他文献来源,如中医经典书籍。总结了PACS的症状以及FMH食物在PACS干预中的应用进展,并进一步讨论了监管特性和食品安全方面的挑战。预计FMH食物的应用将为PACS的治疗和日常干预带来新机遇,本综述为PACS干预食物的开发提供了基础。
Psychopharmacol Bull. 2024-7-8
Cochrane Database Syst Rev. 2022-5-20
Cochrane Database Syst Rev. 2024-12-16
Cochrane Database Syst Rev. 2022-11-17
Cochrane Database Syst Rev. 2022-5-6
J Control Release. 2025-3-10
Front Pharmacol. 2024-12-11
Front Med (Lausanne). 2024-11-20
Chem Pharm Bull (Tokyo). 2024
Medicine (Baltimore). 2024-7-5
J Ethnopharmacol. 2024-10-28
Front Microbiol. 2024-5-28